This is similar to recent preclinical studies reporting that inhibiting different tyrosine kinase receptors or their downstream signaling transducers can sensitize cancer cells to PARPis by reducing expression of BRCA1, BRCA2, RAD51, and other HR components, thereby preventing HR repair [31–33]. Here, RAD51 is linked to cancer.